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Background: Cystic lesions of the pancreas resembling intraductal papillary mucinous neoplasms (IPMN) have been
reported to develop in an increased rate following liver transplantation and immunosuppression. The cause for this
possible association is thus far elusive.
Presentation of the case: We report on a 60-year-old male patient who developed an extensive multicystic change
of the entire pancreas, suspicious for IPMN, under follow-up after liver transplantation for secondary sclerosing
cholangitis. A total pancreaduodenectomy with splenectomy was performed. The postoperative histopathological
assessment revealed a multifocal branch duct IPMN of the gastric subtype showing low-grade dysplasia.
Discussion: In the absence of evidence-based guidelines for the management of suspected IPMNs in liver transplant
recipients, each patient’s management should be discussed in detail.
Conclusion: Prospective studies may help to understand the disease and identify risk factors for malignant transformation
in IPMNs after liver transplantation for treatment optimization.
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Pancreatic cysts are increasingly diagnosed these days.
Recent reports suggested a higher prevalence of
IPMN-like cysts in patients after liver transplantation
and subsequent immunosuppressive therapy. Since
evidence-based guidelines are not established yet an
ideal treatment is still controversially discussed some-
times causing a therapeutic dilemma.
Case presentation
A 60-year-old man was referred to our outpatient clinic
because of persisting lower back pain and hyporexia.
The patient was under follow-up after liver transplant-
ation. Seven years prior to admission, he was treated at
the intensive care unit for third degree burns covering* Correspondence: hanno.matthaei@ukb.uni-bonn.de
1Department of Surgery, University Hospital of Bonn, Sigmund-Freud-Str. 25,
53127 Bonn, Germany
4Center for Integrated Oncology (CIO) Cologne-Bonn, Sigmund-Freud-Str. 25,
53127 Bonn, Germany
Full list of author information is available at the end of the article
© 2015 Branchi et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.approximately 30% of his body surface. During a compli-
cated clinical course, he developed a severe secondary
sclerosing cholangitis with biliary cirrhosis and was
therefore listed for a liver transplantation. In November
2006, 8 months after the accident, he underwent whole
living donor liver transplantation. Subsequently, the pa-
tient received a long-term immunosuppressive therapy
with Tacrolimus, maintained at a blood concentration
between 4.1 and 14.59 ng/ml and Mycophenolate
500 mg every 8 h. He regularly attended follow-up at
our clinic and never suffered from any complications re-
lated to the immunosuppressive treatment regimen.
Routine laboratory tests including blood count, liver
function tests, bilirubin, and C-reactive protein were
normal. He denied alcohol consumption and drug abuse.
Seven years after transplantation, a sonography per-
formed for abdominal discomfort newly diagnosed mul-
tiple cystic lesions in the pancreatic head, body, and tail,
the biggest lesion measuring 3.5 cm in maximum diam-
eter. A magnetic resonance cholangiopancreatography. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cysts involving the entire gland (Figures 1 and 2). The le-
sions were morphologically compatible with a multifocal
branch duct type intraductal papillary mucinous neo-
plasms (BD-IPMN). In order to obtain a biopsy for
histopathological examination, an endoscopic retrograde
cholangiopancreatography (ERCP) was carried out,
which revealed a communication between the cysts and
the dilated main pancreatic duct. Brush cytology showed
papillary epithelium suspicious for IPMN. After thor-
ough discussion in our interdisciplinary, weekly tumor
board surgical resection was recommended. In November
2013, the patient underwent a total pancreatoduode-
nectomy and splenectomy. The histopathological
assessment revealed a multifocal BD-IPMN of the
gastric subtype with low-grade intraepithelial dysplasia
(Figures 3, 4, and 5). No high-grade dysplasia or associ-
ated invasive cancer was detected on a multitude of
sections from the entire specimen, which were inde-
pendently assessed by three experienced pathologists
(HZ, GK, GK). The postoperative course was unevent-
ful, and the patient was discharged on the 14th postopera-
tive day. Seven months after surgery, he presented in a
favorable condition without any relevant complaints.
Discussion
This case reports the development of a multifocal
branch duct type IPMN 7 years after liver transplant-
ation and thus addresses the question regarding a causal
relationship between liver transplantation and immuno-
suppression and the occurrence of cystic neoplasms in
the pancreas. During the past few decades, the develop-
ment of new immunosuppressive drugs and progress inFigure 1 Magnetic resonance tomography (MRT) showing a multifocasurgical and perioperative treatment has led to a better
prognosis after liver transplantation with more than half
of those patients surviving for >20 years [1-3]. Develop-
ment of neoplasms is a severe complication of long time
immunosuppressive therapy [4]. The strong association
between immunosuppression and cancer is nowadays
well understood [5]. Several factors may contribute to
carcinogenesis in liver transplant recipients including
duration, type, and intensity of immunosuppression. As
a consequence, cancer rates after liver transplantation
are two- to threefold higher than in the age- and sex-
matched population [6]. The most frequently observed
neoplasm is post-transplant lymphoproliferative disorder
(PTLD), usually observed relatively shortly after trans-
plantation. Gastrointestinal cancers, in contrast, seem to
be related to long-term immunosuppression [7]. In a
recent large population-based study, the standardized in-
cidence ratio (SIR) for de novo pancreatic cancer after
liver transplantation was between 2.31 and 3.6 [8-11].
The literature about the onset of pancreatic cystic neo-
plasms after liver transplantation is, however, sparse.
Girometti et al. showed that the prevalence of pancreatic
cysts in patients after liver transplantation according to
MRCP imaging was 59.6% [12]. Interestingly, 42.9% of
the detected lesions showed features reminiscent of
IPMN. These rates are considerably higher than in the
general population although the prevalence of pancreatic
cystic lesions in the literature varies considerably
depending on the diagnostic method used. Reported
numbers range from 0.2% on abdominal ultrasound [13],
2.6% on computed tomography (CT) [14] to most repre-
sentative 25% if considering postmortem necropsies in
individuals without known pancreatic disease [15]. Thusl cystic lesion of the pancreas involving the whole organ.
Figure 2 Magnetic resonance cholangiopancreatography (MRCP) with 3D reconstruction demonstrates the multicystic, grape-like
appearance of the lesion.
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incidence of pancreatic cystic lesions following liver
transplantation is influenced by pre- or post-
transplantation factors, such as preoperative pancre-
atic damage (for example, alcohol consumption or
chronic pancreatitis) or postoperative immunosup-
pressive therapy. The clinical situation is certainly
rare, and accordingly, the underlying pathomechan-
isms are poorly understood and no evidence-based
treatment has been established. It is also unknown if
IPMNs developing in patients after liver transplantationFigure 3 Formalin-fixed pancreas specimen that showed multiple cys
only minimally dilated.and immunosuppression have the same biologic behavior
as ‘sporadic’ IPMNs.
There is an agreement that indication for abdominal
surgery should be carefully evaluated in patients with
liver transplants. Apart from possible severe adhesions
due to prior major abdominal surgery, these patients
have a high risk for infectious diseases with subsequent
septic organ dysfunction. Nevertheless, in case of an
IPMN with its potential to develop into a lethal invasive
carcinoma, resection may be the only chance to prevent
the patient from this deadly disease. The decision totic branch duct IPMNs while the main pancreatic duct appears
Figure 4 Hematoxylin and eosin staining showed IPMN-epithelium with merely low-grade dysplasia of the gastric epithelial subtype.
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on the following considerations: our patient had a multi-
focal cystic lesion involving the branch ducts of the
entire pancreatic gland. Preoperative imaging also sus-
pected a partial involvement of the main pancreatic
duct, which appeared dilated up to 10 mm, a ‘worrisome
feature’ implying resection according to the Sendai con-
sensus criteria. Additionally, our patient suffered fromFigure 5 MUC5AC-immunoihstochemical staining of the epithelium cabdominal discomfort as potentially IPMN-associated
symptom. With respect to the usually reduced life
expectancy subsequent to liver transplantation, it is,
however, questionable whether the Sendai criteria should
be equally strictly applied in this patient population.
According to the American Pancreatic Association
(APA) international consensus guidelines in their latest
version, surgical resection should be recommended inonfirmed the presence of gastric-type IPMN.
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pancreatic duct involvement, due to a higher incidence
of invasive cancer (43.1% versus 17.7%) [16,17]. In the
literature, only a few reports are found on patients who
underwent pancreatic surgery after liver transplantation
while the number of liver transplant recipients undergo-
ing major pancreatic surgery for IPMN seems even scar-
cer. A recent retrospective study including 3,196
patients who underwent liver transplantation at the
University of Pittsburgh Medical Center during a period
of 7.5 years demonstrated that 0.6% required pancreatic
surgery in the postoperative course of transplantation
[18]. Of those, merely one patient underwent distal pan-
creatosplenectomy for IPMN while six patients under-
went pancreatectomy for malignant tumors. Stauffer et
al. described a series of 17 patients who were referred to
pancreatic surgery prior to, simultaneously, or after liver
transplantation and reported only one patient who
underwent a pancreaticoduodenectomy for de novo pan-
creatic ductal adenocarcinoma 3.8 years after liver trans-
plantation [19]. Other authors reported single cases of
new onset pancreatic cancer in patients after liver trans-
plantation [20,21]. Del Chiaro et al. presented a patient
who was successfully treated for a BD-IPMN through
enucleation of the cyst 5 years post-liver transplantation
[22]. Lennon et al. recently conducted a monocentric
study to determine the risk of progression in patient
with IPMNs after liver transplantation. In this retro-
spective analysis, 23 liver transplant recipients with BD-
IPMN were compared with a control group of 274
patients who did not undergo liver transplantation and
with no history of immunosuppression [23]. Herein,
17.4% of the liver transplant patient and 16.4% in the
control group developed high-risk features during the
follow-up program. Therefore, no significant increase in
the risk of progression of BD-IPMNs was found in pa-
tients after liver transplantation.
Prospective observation of liver transplant recipients
focusing on cystic pancreatic changes in correlation with
their clinical course will be essential to understand the
conundrum of cyst formation in this patient cohort.
Until we gather more information to develop evidence-
based guidelines, we recommend careful individual man-
agement of every patient and to discuss any treatment in
an experienced interdisciplinary tumor board along with
Sendai recommendations.
Conclusions
Information on an increased occurrence of cystic lesions
such as IPMN after liver transplantation and a possible
etiological coherence is still sparse. From limited data
available and our experience, there is no increased risk
for progression towards invasive adenocarcinoma in this
population. Thus, we recommend a critical and individualpatient-by-patient evaluation in the therapeutic triage
while recommendations from the Sendai consensus cri-
teria should be respected. Patients should be treated in a
tertiary referral center for hepatopancreatobiliary and
transplant surgery/medicine.
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